Maite Bourlon, Associate Professor and Head of the Urologic Oncology Clinic at the National Institute of Medical Sciences and Nutrition Salvador Zubirán, shared posts on X about Advanced Prostate Cancer Consensus Conference:
“The IPCS26 with wonderful data in prostate cancer
- Liquid biopsies
- Neuroendlcrine differentiation
- Epigenetics
- NEMO: Neuroendocrine monitoring panel
- Targeting methylation.”
“Just starting APCCC26!
Silke Gillessen and Aurelius Omlin inaugurating the meeting! Get to know the survey results.”
“10 years of Advanced Prostate Cancer Consensus Conference.
So happy to be a panelist from! Pprostate cancer 1st cause of cancer death in men in the country. More LATAM.”
“High risk localized PCa do we need to add ARPI to ADT+RT?
- Can we identify micro-metastatic disease?
- MFS is a surrogate for OS!
- Tsunami of data is coming!
- Better local and systemic tx! Need New efficacy outcomes!
Cointer-point and balancing!
- Unnecessary, toxic and expenssive
- Selection of patients needed.”
“Surgery in high risk Prostate Cancer!
- Which patients do best w surgery alone? not al high risk are the same!
- Surgery as part of part of mumtimodal approach? Very high risk, cN1, miN1.”
“PSA persistence vs recurrence
- How to treat? SWOG 8794 had a % of patients w more 0.2 PSA…wait NGW02 trial?
- Not every PSA recurrence needs tx!
- PT3, N+, time of recurrence 1-2 y
- When to treat BCR 0.2 or more? You loose benefit!
- How to react?”
“Excellent presentation from Martín Angel presenting the Work of UroTeragLATAM .”
“Congrats to Yüksel Ürün on his participation as speaker.
- Not only OS, we need QoL endpoints!
- Men need coordinated multidisciplinary support
- We need personalized QoL
- Right tx, right patient and right time.”
“Prostate cancer in the elderly!
- Comorbility vs disability vs frailty!
- Life expectancy calculation… then Geriatric screening tool (G-8 is 4 minutes and validated)
- Complexity: local tx, ADT: intensity, type and duration/escalation?”
“Huge discussion in the elderly!
Is there a Lack of benefit in OS w abiraterone in >75 yo? STOPCAP. Consider interactions.”
“Transdermal oestrogen in prostate cancer
- Oral oestrogen vs orchiectomy b/o cardiovascular side effects
- Parenteral avoids first pass low CV toxicity and high bone Health/metabolic profile
NEJM in locally advanced prostate cancer. STAMPEDE efforts ongoing!”
“DAY 3. Last day of Advanced Prostate Cancer Consensus Conference
Do not miss:
- Monitoring patients
- Radioniclide therapy: when, how, no cycles, toxicity
Happy 10th anniversary.”
Other articles featuring Maite Bourlon on OncoDaily.
